Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series

Domingo, E; Camps, C; Kaisaki, P; Parsons, M; Mouradov, D; Pentony, M; Makino, S; Palmieri, M; Ward, R; Hawkins, N; Gibbs, P; Askautrud, H; Oukrif, D; Wang, H; Wood, J; Tomlinson, E; Bark, Y; Kaur, K; Johnstone, E; Palles, C; Church, D; Novelli, M; Danielsen, H; Sherlock, J; Kerr, D; Kerr, R; Sieber, O; Taylor, J; Tomlinson, I

Journal article

Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series

Abstract:: Molecular indicators of colorectal cancer prognosis have been assessed in several studies, but most analyses have been restricted to a handful of markers. We aimed to identify prognostic biomarkers for colorectal cancer by sequencing panels of multiple driver genes.In stage II or III colorectal cancers from the QUASAR 2 open-label randomised phase 3 clinical trial and an Australian community-based series, we used targeted next-generation sequencing of 82 and 113 genes, respectively, including...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Domingo, E., Camps, C., Kaisaki, P., Parsons, M., Mouradov, D., Pentony, M., Makino, S., Palmieri, M., Ward, R., Hawkins, N., Gibbs, P., Askautrud, H., Oukrif, D., Wang, H., Wood, J., Tomlinson, E., Bark, Y., Kaur, K., Johnstone, E., … Tomlinson, I. (2018). Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. Lancet Gastroenterology & Hepatology, 3(9), 635–643.

MLA Style

Domingo, E., et al. “Mutation Burden and Other Molecular Markers of Prognosis in Colorectal Cancer Treated with Curative Intent: Results from the QUASAR 2 Clinical Trial and an Australian Community-Based Series.” Lancet Gastroenterology & Hepatology, vol. 3, no. 9, Elsevier, 2018, pp. 635–43.

Chicago Style

Domingo, E, C Camps, P Kaisaki, M Parsons, D Mouradov, M Pentony, S Makino, et al. 2018. “Mutation Burden and Other Molecular Markers of Prognosis in Colorectal Cancer Treated with Curative Intent: Results from the QUASAR 2 Clinical Trial and an Australian Community-Based Series.” Lancet Gastroenterology & Hepatology 3 (9): 635–43.
Share
Print